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Abstract
BH3-mimetics are a new class of anti-cancer drugs that inhibit anti-apoptotic Bcl-2 proteins. In doing so, BH3-mimetics
sensitise to cell death. Venetoclax is a potent, BCL-2 selective BH3-mimetic that is clinically approved for use in chronic
lymphocytic leukaemia. Venetoclax has also been shown to inhibit mitochondrial metabolism, this is consistent with a
proposed role for BCL-2 in metabolic regulation. We used venetoclax to understand BCL-2 metabolic function. Similar
to others, we found that venetoclax inhibited mitochondrial respiration. In addition, we also found that venetoclax
impairs TCA cycle activity leading to activation of reductive carboxylation. Importantly, the metabolic effects of
venetoclax were independent of cell death because they were also observed in apoptosis-resistant BAX/BAK-deficient
cells. However, unlike venetoclax treatment, inhibiting BCL-2 expression had no effect on mitochondrial respiration.
Unexpectedly, we found that venetoclax also inhibited mitochondrial respiration and the TCA cycle in BCL-2 deficient
cells and in cells lacking all anti-apoptotic BCL-2 family members. Investigating the basis of this off-target effect, we
found that venetoclax-induced metabolic reprogramming was dependent upon the integrated stress response and
ATF4 transcription factor. These data demonstrate that venetoclax affects cellular metabolism independent of BCL-2
inhibition. This off-target metabolic effect has potential to modulate venetoclax cytotoxicity.
Introduction
Anti-cancer therapies often kill cancer cells through the
mitochondrial (intrinsic) pathway of apoptosis1. In this
process, mitochondrial outer membrane permeabilisation
(MOMP) is the key initiating event for cell death2. MOMP
allows the release of mitochondrial proteins, including
cytochrome c, that activate caspase proteases and apop-
tosis. Because of its central role in regulating life and
death, MOMP is tightly regulated, primarily by BCL-2
protein family members. The BCL-2 family is comprised
of pro-apoptotic BAX, BAK and BH3-only proteins and
anti-apoptotic BCL-2 members3. Anti-apoptotic BCL-2
proteins prevent MOMP and cell death by binding acti-
vated BAX, BAK and BH3-only proteins4.
Cancer cells often require increased anti-apoptotic
BCL-2 expression to counteract pro-apoptotic stress, a
state of increased apoptotic priming5. Because of the
central role of BCL-2 proteins in preserving cancer cell
viability, intense effort has centred upon developing drugs
that neutralize anti-apoptotic Bcl-2 function. This has led
to a new class of drugs called BH3-mimetics6. As their
name implies, BH3-mimetics act similarly to BH3-only
proteins, binding anti-apoptotic BCL-2 proteins in their
hydrophobic groove thereby blocking their anti-apoptotic
function. Various BH3-mimetics have been developed
that target select or multiple members of the BCL-2
protein family. To date, venetoclax (also called ABT-199)
represents the archetypal BH3-mimetic7. Developed as a
specific inhibitor of BCL-2, venetoclax is now clinically
approved to treat chronic lymphocyte leukaemia (CML)
and acute myeloid leukaemia (AML)8,9.
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BCL-2 family proteins have been implicated in a variety
of non-apoptotic processes, most notably metabolism.
Regarding BCL-2, reports have shown that BCL-2 over-
expression increases COX activity and therefore promotes
mitochondrial respiration10. Conversely, suppression of
BCL-2 (by shRNA) decreased oxidative phosphorylation
(OXPHOS) activity in primary AML cells11. Venetoclax
has also been shown to affect cellular metabolism, further
implicating BCL-2 in the regulation of metabolism11–13.
Importantly, these metabolic effects of venetoclax have
recently been shown to modulate its efficacy12–14. Never-
theless, how BCL-2 regulates metabolism is unclear. Given
this, we set out to define metabolic functions of BCL-2
using venetoclax as a tool compound. We found that
venetoclax inhibited mitochondrial respiration and tri-
carboxylic acid (TCA) function independent of cell death.
While no effect of BCL-2 loss on metabolism was
observed, surprisingly, venetoclax was found to inhibit
mitochondrial function completely independent of its
target BCL-2. However, the metabolic effect of venetoclax
was dependent on ATF4 transcription factor function.
These results demonstrate that venetoclax can affect cel-
lular metabolism independent of BCL-2 protein inhibition.
Results
Venetoclax affects metabolism independent of
BAX/BAK-mediated cell death
Various studies implicate Bcl-2 family proteins in
metabolic regulation. To understand how BCL-2 might
regulate metabolism, we used venetoclax (also called
ABT-199), a BCL-2 specific BH3-mimetic7. CT26 cells
(murine colorectal cancer cell line) were treated with
venetoclax (1 μM) for 24 h and analysed for mitochondrial
respiratory function by Seahorse extracellular flux assay
(Fig. 1a and Fig. S1A). Venetoclax treatment led to a
decrease in CT26 basal oxygen consumption rate (OCR),
indicating an inhibitory effect on mitochondrial OXPHOS
(Fig. 1a). Maximal OCR (after treatment with the proton
ionophore CCCP) was unaffected following venetoclax
treatment (Fig. 1a). Cells can compensate for lower
mitochondrial respiration by increasing glycolysis15.
Consistent with upregulation of glycolysis, we observed
an increased uptake of glucose and lactate secretion in
medium following treatment of CT26 cells with veneto-
clax (24 h, 1 μM) (Fig. 1b). To define if the effects of
venetoclax on OCR were immediate, CT26 cells were
treated with venetoclax (1 μM) and mitochondrial OCR
was assessed over a 4-h time period. Venetoclax did not
induce an immediate drop in OCR, however an effect
became apparent after 4 h treatment (Fig. S1B). We
extended our analysis to a panel of cell lines (human
colorectal cancer; HCT116, human breast cancer; MCF7
and human AML; OCI-AML-3) analysing mitochondrial
respiratory function by Seahorse assay following
venetoclax treatment (24 h, 1 μM) (Fig. 1c). In all cases,
basal OCR was reduced following venetoclax treatment,
indicating that venetoclax inhibition of mitochondrial
function is independent of cell types tested. During
apoptosis, MOMP is associated with a rapid loss of
mitochondrial respiratory function16. Consequently, the
metabolic effects of venetoclax treatment might be sec-
ondary to cell death caused by neutralisation of anti-
apoptotic BCL-2 function. To investigate this possibility,
CT26 and MCF7 cells were treated with venetoclax
(1 μM) and analysed for cell viability by Sytox Green
exclusion and Incucyte live-cell analysis (Fig. 1d). Treat-
ment with venetoclax alone had no impact on cell viability
over a 48-h period in both cell lines whereas combined
treatment of venetoclax with S63845 (MCL-1 targeting
BH3-mimetic)17 induced cell death in MCF7 cells
(Fig. 1d). This result argues that the metabolic effects of
venetoclax are independent of cell death. To definitively
address this, we used CRISPR/Cas9 genome editing to
generate CT26 cells deficient in BAX and BAK—two
proteins that are essential for mitochondrial apoptosis
(Fig. 1e)18,19. As expected, BAX/BAK deleted CT26 cells
were completely resistant to a combination of BH3-
mimetics (ABT-737 and S63845, 10 and 1 μM, respec-
tively, added to inhibit BCL-2, BCL-xL, BCL-W and
MCL-1) (Fig. S1C). Using these cells, we analysed the
effect of venetoclax treatment in metabolism by analysis
of extracellular metabolite levels (Fig. 1f) and mitochon-
drial respiratory function (Fig. 1g). Venetoclax treatment
led to a decrease in basal OCR, and increase in glucose
uptake and lactate secretion independent of BAX and
BAK. These data demonstrate that the BCL-2 targeted
BH3-mimetic venetoclax can affect cellular metabolism
independent of its canonical pro-apoptotic function.
Venetoclax inhibits the TCA cycle causing reductive
carboxylation
We aimed to understand how venetoclax affects meta-
bolism. Because we had detected alterations in glucose
uptake and lower mitochondrial respiration following
venetoclax treatment, we focused on metabolites involved
in the TCA cycle, also known as the citric acid cycle. The
TCA cycle is a series of redox reactions carried out in the
mitochondrial matrix mainly supported by two carbon
sources: (1) glucose, which provides carbons, through its
glycolytic conversion into pyruvate and then into acetyl-
CoA and (2) glutamine that is converted into glutamate
and then into α-ketoglutarate (α-KG). To investigate
potential effects of venetoclax on the TCA cycle, CT26
cells were treated with venetoclax (1 μM, 24 h) and
intracellular metabolite levels were analysed by LC–MS
(Fig. 2a). A variety of TCA metabolite levels were altered
following venetoclax treatment, specifically α-KG and
succinate levels were increased while citrate and malate
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were unaltered (Fig. 2a). Glutamine enters the citric acid
cycle as α-KG (via glutaminolysis) and is then converted
to succinate. Alternatively, through reductive carboxyla-
tion, the TCA cycle can operate in reverse, converting α-
KG to citrate (Fig. 2b). The succinate accumulation that
we observed suggested an inhibition in TCA cycle,
therefore, to analyse TCA function, we employed stable
isotope tracing using labelled 13C-glucose or 13C-
glutamine. The respective labelled metabolites were
added with or without venetoclax treatment (1 μM, 24 h)
to CT26 cells and intracellular metabolites were analysed
by LC–MS. Higher label incorporation was found in TCA
cycle metabolites using 13C-glutamine (Fig. S2A) com-
pared with 13C-glucose (Fig. S2B), indicating that gluta-
mine is the main substrate for the TCA cycle in these
cells. Consequently, we analysed different metabolites
following 13C-glutamine labelling. This analysis showed
that venetoclax treatment increased the levels of gluta-
mate m+5 (Fig. S2C) and α-KG m+5 (Fig. 2d and
Fig. S2A) demonstrating increased glutamine metabolism.
In line with this, the increase of total succinate levels was
found mainly as succinate m+4 (Fig. 2d and Fig. S2A).
Consistent with an inhibition of the TCA cycle by vene-
toclax, we also observed an increased in labelled citrate
m+5 and malate m+3, indicative of reductive carbox-
ylation (Fig. 2c, d and Fig. S2A). Collectively these data
demonstrate that venetoclax inhibits the mitochondrial
TCA cycle, and suggest an activation of reductive car-
boxylation upon treatment.
Metabolic effects of venetoclax are independent of Bcl-2
protein inhibition
Because venetoclax is a BCL-2 specific BH3-mimetic,
our data implicated BCL-2 in the regulation of metabo-
lism. To investigate this, we determined whether targeting
BCL-2 with alternative BH3-mimetics, S55746 (specific
for BCL-2)20 or ABT-737 (targeting BCL-2, BCL-xL and
BCL-W)21 had similar metabolic effects. CT26 cells were
treated with ABT-737 or S55746 (1 μM for 24 h) and
analysed for OCR by Seahorse assay (Fig. 3a, b). Unlike
venetoclax, neither ABT-737 nor S55746 decreased OCR.
In a second approach, we performed metabolic tracing
using labelled 13C-glutamine, with or without S55746
treatment. In contrast to venetoclax (Fig. 2), S55746
treatment did not affect the labelling or levels of TCA
metabolites (Fig. S3A). Surprisingly, these data demon-
strate that additional BH3-mimetics that target BCL-2 do
not phenocopy the metabolic effects of venetoclax. We
reasoned this disparity in two ways; (1) either venetoclax
binds BCL-2 in a distinct manner that affects metabolism
or (2) venetoclax affects metabolism independent of BCL-
2 binding. To discern these possibilities, we used CRISPR/
Cas9 genome editing to generate BCL-2 deleted CT26
cells (Fig. 3c) and BCL-2 deleted SVEC4-10 (SV40
immortalised murine endothelial cell line) (Fig. S3B).
Deletion of BCL-2 itself had no effect on basal OCR,
determined by Seahorse assay (Fig. 3d and Fig. S3B), or
TCA metabolite levels (Fig. 3e and Fig. S3B). We next
treated BCL-2 deleted CT26 cells with venetoclax and
assessed OCR (Fig. 3f). Crucially, venetoclax also inhibited
OXPHOS in BCL-2 deleted cells. Extending this, we
analysed extracellular metabolite levels (Fig. 3g) or TCA
metabolites (Fig. 3h) in BCL-2 deleted cells following
venetoclax treatment. An increase in glucose uptake and
lactate release was observed following treatment, irre-
spective of BCL-2 expression (Fig. 3g). Moreover, similar
to what we had observed previously, venetoclax induced
an increase in α-KG and succinate levels that, again, was
independent of BCL-2 (Fig. 3h). As an alternative
approach, RNAi was used to inhibit BCL-2 expression in
CT26 cells (Fig. S3C). Following venetoclax treatment,
succinate levels were again increased and mitochondrial
respiration was also decreased, irrespective of BCL-2
expression (Fig. S3D, E). To expand these findings, we
generated BCL-2 deleted B16F10 murine melanoma cells
using CRISPR/Cas9 genome editing (Fig. S3F). These cells
were treated with venetoclax (1 μM, 24 h) and OCR was
analysed by Seahorse assay (Fig. S3G) or TCA metabolite
levels by LC–MS (Fig. S3H). Irrespective of BCL-2
expression, venetoclax inhibited mitochondrial OCR
(see figure on previous page)
Fig. 1 Venetoclax affects metabolism independent of BAX/BAK-mediated cell death. CT26 cells were treated with venetoclax (1 μM) for 24 h
then oxygen consumption rate (OCR) was measured by Seahorse XF-96 Analyzer. a Basal OCR and maximal respiration. Data are the mean of three
independent experiments ± SEM. b CT26 vector control cells were treated with venetoclax (1 μM) for 24 h, then glucose and lactate levels in the
medium was measured by Biochemistry Analyzer YSI. Data represent the mean of four independent experiments ± SEM. c Basal OCR of HCT116
(mean of four independent experiments ± SEM), MCF7 (mean of one representative experiment, with six technical replicates, of two independent
experiments), OCI-AML3 (one representative experiment, [mean of eight technical replicates], of two independent experiments). d CT26 or MCF7 cells
were treated with venetoclax (1 μM) and S63845 (1 μM), alone or in combination for the indicated time points and cell viability was monitored with
Sytox Green exclusion and Incucyte live-cell imaging. Data represent the mean of three independent experiments ± SEM. e Expression of BAX and
BAK from CT26 CRISPR-EMPTY or CRISPR-BAX/BAK cells was measured by western blot, α-tubulin was included as a loading control. CT26 CRISPR-
EMPTY or CRISPR-BAX/BAK were treated with venetoclax (1 μM) for 24 h, then metabolites were measured from media (f) and OCR was determined
(g). Data represent the mean of four (f) or three (g) independent experiments ± SEM. Samples were compared using two-tailed, unpaired Student’s
t test. *p < 0.05, **p < 0.01, ***p < 0.001.
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Fig. 2 Venetoclax inhibits the TCA cycle causing reductive carboxylation. a CT26 cells were treated for 24 h with venetoclax (1 μM) and
intracellular metabolites were extracted and analysed by LC–MS. Total levels of metabolites are shown from three independent experiments ± SEM.
b Diagram showing carbon labelling when cells are cultured with 13C-glutamine. c, d CT26 cells were treated for 24 h with venetoclax (1 μM) and
cultured with labelled glutamine (13C-GLN). Labelled metabolites from three technical replicates of one representative experiment (out of two).
Samples were compared using two-tailed, unpaired Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.
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and increased α-KG and succinate levels. These data
demonstrate that venetoclax affects cellular metabolism
independently of its pro-survival target BCL-2. Finally, as
venetoclax still has some affinity, albeit significantly lower,
for other Bcl-2 proteins7 we investigated whether vene-
toclax effects on mitochondrial respiration were depen-
dent on other anti-apoptotic BCL-2 family members. For
this purpose, we used HCT116 cells deficient in all Bcl-2
family members, except BOK - called Bcl-2 allKO
HCT11622. Bcl-2 allKO HCT116 cells were treated with
venetoclax and analysed for OCR by Seahorse assay
(Fig. 3i). Venetoclax also inhibited basal OCR in this
setting. These data demonstrate that venetoclax affects
cellular metabolism independent of its cognate target
BCL-2 and Bcl-2 family proteins in general.
Venetoclax affects mitochondrial morphology and
function
We next sought to understand how venetoclax affected
metabolism independent of BCL-2. Due to the effects
previously observed (reduced OCR and inhibition of TCA
cycle), we first asked whether venetoclax treatment
affected mitochondrial morphology. Control or BCL-2
deleted B16F10 cells were treated with venetoclax (1 μM,
24 h) and mitochondrial morphology was analysed by
electron microscopy (EM) (Fig. 4a, b). While BCL-2
deletion had no effect on mitochondrial morphology,
venetoclax treatment led to mitochondrial enlargement
independent of BCL-2 (Fig. 4a, b). To extend this finding,
we also analysed mitochondrial morphology in another
cell line, MCF7, following venetoclax treatment (1 μM,
24 h) (Fig. S4). Treatment with venetoclax (1 μM, 24 h)
also led to aberrant mitochondrial morphology in MCF7
cells. Because venetoclax affected mitochondrial mor-
phology, we investigated whether venetoclax could affect
mitochondrial activity, focusing on electron transport
chain function. CT26 cells were treated with venetoclax
(1 μM, 24 h) and the activity of respiratory complexes I, II
and IV was measured by Seahorse analysis (Fig. 4c).
Importantly, venetoclax inhibited the activity of all
respiratory complexes tested (Fig. 4c). Finally, we
investigated effects of venetoclax dose dependency. CT26
cells were treated for 24 h with varying concentrations of
venetoclax (50 nM–1 μM) and assayed for complex
activity using Seahorse assay (Fig. 4d). At 1 μM veneto-
clax, the function of all respiratory complexes was affec-
ted; however, at a lower dose (50 nM), complex I activity
was unaffected, whereas complex IV activity was still
inhibited, and complex II only partially (Fig. 4d). Collec-
tively, these data demonstrate that venetoclax alters
mitochondrial morphology independent of BCL-2 inhi-
bition and broadly inhibits mitochondrial respiratory
complex function.
Venetoclax affects metabolism dependent on ATF4
We next investigated how venetoclax could affect
mitochondrial ETC function. Given its broad effects on
complexes I, II and IV activity, we reasoned that veneto-
clax may impact on respiratory complex assembly. To
investigate this, MCF7 cells were treated with venetoclax
(1 μM, 24 h) and ETC complex integrity was assessed by
blue native gel (Fig. S5). However, venetoclax had no
effect on respiratory complex assembly. We had pre-
viously observed that venetoclax effects on oxygen con-
sumption are not immediate (Fig. S1B). This delayed
effect might be due to venetoclax regulating OXPHOS in
an indirect manner. Mitochondrial stress can elicit a
process called the integrated stress response (ISR) char-
acterised by phosphorylation of eIF2α and upregulation of
the transcription factor ATF423. Consequently, we
investigated whether venetoclax treatment led to ISR
activation. CT26 cells were treated with venetoclax or
S55746 (1 μM, 24 h) and analysed by for phospho-eIF2α
and ATF4 levels by western blot (Fig. 5a). Importantly,
venetoclax treatment increased phospho-eIF2α and ATF4
levels, consistent with engagement of the ISR, whereas
S55746 had no effect. ATF4 is known to regulate meta-
bolic adaptation through the transcription of various
metabolic enzymes24. We therefore investigated whether
venetoclax altered mitochondrial metabolism in an ATF4-
dependent manner. To this end, we used RNA inter-
ference to effectively supress ATF4 expression in CT26
(see figure on previous page)
Fig. 3 The metabolic effects of venetoclax are independent of BCL-2 family proteins. a CT26 cells were treated for 24 h with ABT-737 (1 μM)
and OCR was measured. Data represent the mean of five technical replicates from one representative experiment (out of two). b CT26 cells were
treated for 24 h with S55746 (1 μM) and OCR was measured. Data represent the mean of five technical replicates from one representative experiment
(out of two). c BCL-2 protein expression in CT26 CRISPR-EMPTY and CT26 CRISPR-BCL2 cells was determined by western blot, α-tubulin was probed as
a loading control. d OCR of CT26 CRISPR-EMPTY and CT26 CRISPR-BCL2 cells. Data represent the mean of five independent experiments ± SEM.
e Metabolite levels of CT26 CRISPR-EMPTY and CT26 CRISPR-BCL2 cells. Data represent the mean of three technical replicates. CT26 CRISPR-EMPTY
and CT26 CRISPR-BCL2 cells were treated with venetoclax (1 μM) for 24 h; OCR was assessed (f), metabolites from the media were measured (g), and
intracellular metabolites were extracted and analysed by LC–MS (h). Data represent the mean of three independent experiments ± SEM (f, g) or one
independent experiment with three technical replicates (h). i Basal OCR of Bcl-2 allKO HCT116 cells after treatment with venetoclax (1 μM) for 24 h.
Data represent the mean of four independent experiments ± SEM. Samples were compared using two-tailed, unpaired Student’s t test. *p < 0.05,
**p < 0.01, ***p < 0.001 and ****p < 0.0001.
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cells (Fig. 5b). Using this approach, we assessed the
requirement for ATF4 in venetoclax-induced mitochon-
drial OXPHOS inhibition (Fig. 5c). Importantly, ATF4
loss prevented the venetoclax-induced reduction in OCR.
To study this further we investigated effects of venetoclax
on TCA metabolites with or without ATF4 (Fig. 5d). In
line with our previous findings, venetoclax induced
increases in succinate was partially rescued by depletion
of ATF4. In addition, activation of reductive carboxylation
induced by venetoclax (assessed by increase in citrate
m+5 and malate m+3) was also decreased upon loss of
ATF4 expression. In sum, these data demonstrate that
venetoclax activates the ISR, leading to ATF4-dependent
metabolic reprogramming.
Fig. 4 Venetoclax affects mitochondrial morphology and function. a TEM images from B16F10 CRISPR-EMPTY and CRISPR-BCL2 cells after 24 h of
venetoclax (1 μM) treatment. Scale bar= 1 μm. b A random selection of at least 25 mitochondria across different cells and fields was analysed for
each condition from images in a. Mitochondrial area (in μm2) was quantified using ImageJ software. Data represent the mean of at least 25
mitochondria ± SEM. c CT26 cells were treated for 24 h with venetoclax (1 μM), then activity of complexes I, II and IV was assessed by Seahorse XF-96
Analyzer. Complex I data represent the mean of two independent experiments; complex II data represent the mean of four independent
experiments ± SEM and complex IV data represent the mean of three independent experiments ± SEM. d CT26 cells were treated for 24 h with
vehicle, venetoclax (1 μM) or venetoclax (50 nM), then activity of complexes I, II and IV was assessed. Data represent the mean of one independent
experiment with four technical replicates. Samples were compared using two-tailed, unpaired Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.
Ven = venetoclax.
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Discussion
Venetoclax is a potent, clinically approved BH3-mimetic
that induces apoptosis by targeting BCL-27. Recent studies
have shown that venetoclax also has metabolic effects,
thereby implicating BCL-2 in the regulation of metabo-
lism11–14. Our initial goal was to use venetoclax to
understand the metabolic functions of BCL-2. Similar to
others, we also found that venetoclax exerts metabolic
effects—decreasing mitochondrial respiration and inhi-
biting the TCA cycle. The metabolic effects of venetoclax
were found to be independent of the canonical, pro-
survival function of BCL-2, because they were also
observed in apoptosis-resistant BAX/BAK-deficient
cells. Crucially, venetoclax also affected mitochondrial
Fig. 5 Venetoclax affects metabolism dependent on ATF4. a Expression of ATF4, P-eIF2α and eIF2α from CT26 cells treated with venetoclax or
S55746 (1 μM, 24 h) was measured by western blot, HSP60 was included as a loading control on the same blot. b ATF4 protein expression in CT26
cells following transfection with non-targeting siRNA (NTC) or siRNA against Atf4 was determined by western blot, α-tubulin was probed as a loading
control on the same blot. c NTC or ATF4 siRNA transfected CT26 cells were treated with venetoclax (1 μM) for 24 h and assessed for OCR. Data
represent the mean of three independent experiments ± SEM. d NTC or ATF4 siRNA transfected CT26 cells were treated with venetoclax (1 μM) for
24 h and cultured with labelled glutamine (13C-GLN). Intracellular metabolites were extracted and analysed by LC–MS. Graphs represent total
succinate levels and relative citrate m+5 and malate m+3 levels of one independent experiment with three technical replicates. Samples were
compared using two-tailed, unpaired Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001. Ven = venetoclax, S55 = S55746.
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metabolism in BCL-2 deficient cells and, indeed, in cells
lacking all anti-apoptotic Bcl-2 family members. This
demonstrates that venetoclax can affect metabolism
independent of its BCL-2 inhibitory function. Investigat-
ing the underlying basis for these metabolic effects, we
found that they were dependent on activation of the ISR
and the transcription factor ATF4.
Using apoptosis-resistant BAX/BAK-deficient cells, our
data definitively show that venetoclax can decrease
mitochondrial respiration independent of cell death.
Supporting this view, other studies have found that
venetoclax can inhibit respiratory function in the absence
of obvious cell death12,13. Nevertheless, a recent study has
shown that venetoclax-impairment of OXPHOS at short-
time points post-treatment requires BAX/BAK-depen-
dent MOMP14. This is somewhat expected, given the
well-established inhibitory effects of MOMP on mito-
chondrial respiration16. Importantly, the cell death (BAX/
BAK independent) effects of venetoclax treatment we
observed occurred upon prolonged treatment. This is
consistent with our finding that the ISR and ATF4 tran-
scriptional activity are required for venetoclax dependent
metabolic effects.
Our study’s rationale was to use venetoclax to probe
how BCL-2 could regulate metabolism. Various studies
have implicated a role for BCL-2 in the regulation of
mitochondrial metabolism10,11. However, during our
investigation of venetoclax activity, we failed to observe
any effect of suppressing BCL-2 expression (either via
RNAi or CRISPR/Cas9 genome editing) on mitochondrial
function in different cell lines. There could be many
reasons for this, including artefactual effects of BCL-2
overexpression upon mitochondrial function, cell type
specific effects and/or indirect effects of BCL-2 affecting
metabolism, for instance, through effects on cell viability.
Our surprising finding was that venetoclax could inhibit
mitochondrial respiration independent of its target
BCL-2. This is supported by different lines of evidence
including data that other BH3-mimetics that target
BCL-2, including S55746 and ABT-737, failed to exert any
metabolic effect. Most conclusively, venetoclax also
inhibited mitochondrial respiration in cells deficient in
BCL-2 and, indeed, in cells devoid of all anti-apoptotic
Bcl-2 proteins. Importantly, this precludes using veneto-
clax as tool to define BCL-2 metabolic effects.
A remaining question is how does venetoclax affect
mitochondrial function independent of BCL-2? Towards
answering this, we found that venetoclax affected mito-
chondrial morphology, again independent of its target
BCL-2. Alterations in mitochondria morphology have
been observed in several mitochondrial pathologies25,26.
For instance, cancers that harbour mutations in the TCA
cycle protein fumarate hydratase, present a disrupted
TCA cycle27, impaired OXPHOS, increased glycolysis and
abnormal mitochondrial morphology28,29, phenocopying
the observed effects induced by venetoclax. Based on
these and many other studies, we consider it likely that
venetoclax-induced mitochondrial dysfunction leads to
aberrant mitochondrial morphology. In addition, it has
been reported that the shape of mitochondrial cristae
determines the efficiency of mitochondrial respiration30,
demonstrating a link between mitochondrial morphology
and function. In line with this, analysis of electron
transport chain function (complexes I, II, IV) showed that
venetoclax displayed broad inhibitory activity. Corrobor-
ating our findings, others have recently shown that
venetoclax can inhibit complex I activity13. Importantly,
other studies have described synergy between ETC inhi-
bitors with venetoclax treatment14,31. Thus, the respira-
tory effects of venetoclax we describe here may contribute
to this synergistic effect. Nevertheless, we suspect that
these effects on respiratory complex function are most
likely indirect, due to the lag time between addition of
venetoclax and inhibition of mitochondrial metabolism.
This prompted us to investigate alternative possibilities,
where we found that the metabolic effects of venetoclax
were dependent on the transcription factor ATF4. ATF4
has been described as the master regulator of mitochon-
drial stress, activated as part of the ISR32. Various studies
have found that the ISR and ATF4 can be activated upon
chemotherapy and contribute to chemoresistance33–35.
Moreover, within the tumour microenvironment, stromal
fibroblasts can also upregulate ATF4 to induce metabolic
changes that promote tumour proliferation36. Never-
theless, ATF4 can have opposing activities; upon a mild
stress, it can restore cellular homoeostasis, whereas upon
an excessive or prolonged stress, ATF4 activity can cause
cell death23. Along these lines, ATF4 has recently been
shown to promote or circumvent resistance to veneto-
clax13,31,37. As such, the off-target ATF4 effect we describe




All cell lines were cultured at 37 °C in a humified
incubator with 5% CO2. SVEC4-10, B16F10, MCF7,
HCT116 and HEK-293FT cells were maintained in Dul-
becco’s modified Eagle’s medium (DMEM), high glucose
medium (25mM). CT26, OCI-AML3 cells were cultured
in RPMI medium. All media were supplemented with 10%
FBS, 2 mM glutamine, 1 mM sodium pyruvate and 50 μM
β-mercaptoethanol. All the cell lines were determined
negative for mycoplasma.
Cell viability assays
Cell viability was monitored by Incucyte imaging system
(Incucyte FLR, Incucyte ZOOM or Incucyte S3 Live-Cell
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Analysis System from Essen Bioscience), using the non-
cell-permeable nuclear stain 30 nM SYTOX Green (SG,
S7020, Invitrogen), according to the manufacturer’s pro-
tocols. The number of SYTOX Green-positive cells was
normalized to cell confluence in each well. In every
experiment, two technical replicates were performed and
experiment was independently repeated three times.
Lentiviral transduction
HEK-293FT (2 × 106) cells were co-transfected with the
indicated target plasmids and the packaging plasmids
psPAX (Addgene, 12260) and pCMV-VSV-G (Addgene,
8454), using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s instructions.
After 2 days, the viral supernatant produced from HEK-
293FT cells was filtered (0.45 μm) and used to infect
selected cells, in the presence of 1 μg/mL polybrene. After
two rounds of infection, positive CRISPR/CAS9-deleted
cells were selected by antibiotic (10 μg/mL of blasticidin
and 1 μg/mL puromycin) for all cell lines, except CT26,
which were selected with 10 μg/mL of puromycin. Plas-
mids: CRISPR-guide sequences: murine BCL2 (AGAA
GTCATCCCCAGCCCGG), murine BAX (CAACTTCA
ACTGGGGCCGCG), murine BAK (GCGCTACGACA
CAGAGTTCC).
siRNA transfection
siRNA transfection was performed in a six-well plate
(1 × 105 cells per well). Cells were cultured in antibiotic-
free medium (800 μL) and transfected with 200 μL of
Optimem medium (Thermo Scientific) containing 20 or
50 nM non-targeting control (si scramble, D-001206-13-
05, Dharmacon), siRNA-targeting Bcl2 (siGENOME
SMARTpool (mouse), M-063933-01-0005, Dharmacon),
siRNA-targeting Atf4 (siGENOME SMARTpool (mouse),
M-042737-01-0005, Dharmacon) using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s pro-
tocol. After 5 h of incubation, cells were washed with PBS
and fresh medium containing antibiotic (10000 units/mL
penicillin) was added.
Western blotting
Cells were lysed in RIPA buffer (10 mM Tris-HCl (pH
7.4), 150 mM NaCl, 1.2 mM EDTA, 1% Triton, 0.1%SDS)
for 20min. Afterwards, protein lysates were centrifuged at
maximum speed (21130 rcf) for 10 min, at 4 °C. Protein
quantification was performed using Pierce™ BCA Protein
Assay (Thermo Fisher, 23250) according to the manu-
facturer’s protocol. Then, SDS-containing loading buffer
(NuPAGE™ LDS Sample Buffer, NP0007) and DTT were
added to the lysates (final concentration of 1x and 10mM,
respectively) for protein denaturation. Samples were
boiled for 5 min at 100 °C before loading onto the gel.
Proteins were separated by SDS-PAGE in Bio-Rad
Western blot chambers (80–120 V) and then transferred
onto nitrocellulose membrane (100 V for 1–1:30 h).
Membranes were incubated with the primary antibody
(5% milk or BSA in TBS-T) overnight at 4 °C. Then, they
were incubated with the secondary antibody (5% milk in
TBS-T) (Li-COR Biosciences) for 1 h at room temperature
in the dark. Protein detection was achieved by Odyssey®
Imaging Systems CLx (Li-COR Biosciences). Primary
antibodies: HSP60 (Cell Signaling, 4870, 1/1000), ATF4
(D4B8) (Cell Signaling, 11815, 1/500), Phospho-eIF2α
(Ser51) (D9G8) (Cell Signaling, 3398, 1/500), eIF2α
(D7D3) (Cell Signaling, 5324, 1/500), BCL-2 (10C4)
(Santa Cruz, sc-23960, 1/500), α-tubulin (Sigma, T5168:
1/1000), BAK (D4E4) (Cell Signaling, 12105, 1/1000),
BAX (Cell Signaling, 2772, 1/1000). Control panels were
generated by assessing the expression of a housekeeping
gene (HSP60 or α-tubulin) on the same blot.
Mitochondrial respiration experiments
For mitochondrial respiration experiments, 10,000 cells/
well were seeded in XFe96 plates (Agilent). Next day, cells
were treated during 24 h with DMSO or drug treatment.
After 24 h of treatment, the medium was aspirated, and
replaced with the XF Mito stress medium (DMEM or
RPMI supplemented with 1% FBS, 10 mM glucose, 2 mM
glutamine, and 1mM pyruvate, pH 7.4). Cells in XF Mito
stress medium were incubated at 37 °C in the absence of
CO2 for 30–45min. OCR was measured using the XFe96
Extracellular Flux Analyzer (Agilent) according to the
manufacturer’s instructions. Baseline OCR measurements
were determined before administration of oligomycin
(1 μM) (port A). Then, CCCP (1.5 μM) was added in port
B, and a combination of rotenone (1 μM) and antimycin A
(1 μM) in port C. After seahorse assay, OCR measure-
ments were normalized to the amount of protein per well.
Protein O.D. was measured using Pierce™ BCA Protein
Assay (Thermo Fisher, 23250) according to the manu-
facturer’s protocol. For suspension cells (OCI-AML3), the
plate was first pre-coated with 25 μL of Cell-Tak (Corn-
ing™ Cell-Tak Cell and Tissue Adhesive; Fisher Scientific,
10317081) solution at 0.02 mg/mL in 0.1M NaHCO3, pH
6–8. Then, 80,000 cells/well were seeded in XFe96 plates
(Agilent) in 50 μL of XF Mito stress medium (RPMI
supplemented with 1% FBS, 10 mM glucose, 2 mM glu-
tamine, and 1mM pyruvate, pH 7.4). Then, the plate was
centrifuged at 200 × g for 1 min, without brakes and
incubated for 20–30min at 37 °C in a CO2-free incubator.
After incubation, 100 μL of seahorse medium was added
to each well. Finally, the plate was incubated during
another 20 min more at 37 °C in a CO2-free incubator.
Seahorse analysis was carried out as described previously.
Cell number was used for normalization of OCR values.
Data analysis was conducted with the Seahorse Wave
software version 2.2.0.276 (Agilent).
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Activity of mitochondrial respiratory complexes
For cell permeabilization experiments, cells were seeded
in XFe96 plates, as described before in the previous sec-
tion, and treated with DMSO or 1 μM of drug treatment
for 24 h. Cell medium was removed, and manitol and
sucrose buffer (MAS-BSA) was added (MAS: 220mM
mannitol, 70 mM sucrose, 10 mM KH2PO4, 5 mM MgCl2,
2 mM HEPES, 1 mM EGTA, 4 mg/mL fatty acid free BSA,
pH= 7.20). Cells in MAS buffer were incubated at 37 °C
in the absence of CO2 for 10min. Baseline OCR mea-
surements were recorded before administration of per-
meabilizer (saponin, SAP: 40 μg/mL) and complex
substrate (complex I: 10 mM pyruvate, 5 mM malate;
complex II: 10 mM succinate, 1 μM rotenone; complex
IV: 0.5 mM TMPD, 2mM ascorbate). ADP (1 mM) was
also added in all conditions and pH was adjusted to 7.2.
Maximal respiration was assessed before treatment with
oligomycin A (1 μM) and finally complex inhibitors were
injected to abolish respiration (complex I: 1 μM rotenone,
complex II: 2 μM antimycin A, complex IV: 20 mM azide).
OCR measurements were normalized to protein O.D. as
described before. Data analysis was conducted with the
Seahorse Wave software version 2.2.0.276 (Agilent).
Extracellular metabolite analysis
A total of 50,000 cells/well were seeded in 12-well
plates. Next day, media was replaced with fresh media
(800 μL), with either DMSO or treatment, and cell density
was measured (t= 0). After 24 h of treatment, media was
collected and cell number was determined in each well
(t= 24). Media collected was kept at −80 °C until samples
were run. Two hundred microlitres of each sample were
transferred to 96-well plates and concentration of gluta-
mate, glucose, lactate and glutamine was determined with
a 2950 Biochemistry Analyzer (YSI). Exchange rates were
calculated and normalised to cell number. Three technical
replicates were used in every independent experiment. At
least three independent experiments were performed.
Metabolite analysis by LC–MS
On ice, cells were washed three times in cold PBS before
adding 500 μL of extraction buffer (methanol, acetonitrile,
and water (5:3:2) v/v) at 4 °C. After 5 min at 4 °C, buffer
was transferred to Eppendorf tubes and spun for 10min,
12,000 rcf at 4 °C. Supernatants were transferred into
HPLC vials and stored at −80 °C prior to LC–MS analysis.
Metabolite analysis was performed using LC–MS as
described in ref. 38. Briefly, polar metabolites in the
samples were measured using HILIC chromatography and
full scan mass spectrometry on a Thermo Q Exactive
mass spectrometer. Commercial standards of all detected
metabolites were run on the system prior to analysis. Peak
areas of the metabolites were identified by a combination
of mass and retention time using Thermo TraceFinder
software. Peak areas of each sample were normalized to
amount of protein. Quantification of protein was per-
formed by the Modified Lowry method according to the
manufacturer’s protocol. Representation of normalized
absolute or relative peak areas was performed using
GraphPad Software Prism 6 or Metabolite AutoPlotter
(https://mpietzke.shinyapps.io/AutoPlotter/). Three tech-
nical replicates were performed per experiment.
Transmission EM
Cells were fixed in 0.1M sodium cacodylate buffer
containing 2.5% glutaraldehyde, during 10min at RT and
then 1 h at 4 °C. Post fixation was performed with 1%
osmium tetroxide/0.1 M sodium cacodylate buffer for 1 h
in the dark. Then, en bloc stained with 0.5% aqueous
uranyl acetate for 1 h in the dark and processed in a
standard manner. Samples were fresh resin embedded in
flat bed moulds and left for polymerisation. Then,
embedded samples were cut in 60–70 nm ultrathin sec-
tions (LEICA Ultra Cut UCT) and contrast stained with
2% methanolic uranyl acetate during 5min and Reynolds
lead citrate during 5min. Samples were viewed on a JEOL
1200EX transmission electron microscope (TEM) at an
accelerating voltage of 80 kV. TIF images were captured
using a 2Kx2K digital camera (Cantega) and iTEM
(Olympus) as the software imaging system. A random
selection of at least 20 mitochondria across different cells
and fields was analysed for each condition. Then, mito-
chondrial area was quantified using ImageJ software.
Blue native polyacrylamide gel electrophoresis
Cells were pelleted and resuspended in NativePAGE
Sample Buffer (1x) (Thermo Fisher Scientific, BN2003)
with 1% digitonin. Then, centrifuged at 20,000 × g for
30 min at 4 °C. Protein concentration in supernatant was
determined by BCA protein assay and then samples were
kept at −80 °C. One hundred micrograms of protein
lysates were loaded into NativePAGE 3–12% Bis-Tris
Protein Gels (Thermo Fisher Scientific, BN1001BOX).
Electrophoresis and consequent western blotting were
performed using the NativePAGE Novex Bis-Tris Gel
System (Thermo Fisher Scientific) as described in the
manufacturer’s protocol. After transfer, membrane was
incubated in 8% acetic acid for 15min to fix the proteins.
Then, blocking, washing and primary antibody incubation
steps were performed as described previously on “Wes-
tern blotting” section. After primary antibody incubation,
membranes were incubated with ECL mouse IgG, HRP-
antibody (GE Healthcare Life Sciences, NA931). Proteins
bands were detected using Clarity Max Western ECL
Substrate (Bio-Rad, 1705062) and ChemiDoc Imaging
System (Bio-Rad, 17001401).
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Statistical analysis
All data are represented as mean ± SEM. Samples were
compared using two-tailed, unpaired Student’s t test,
*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. Sta-
tistical analysis was performed using Prism version 6.0c
(GraphPad Software, La Jolla, CA).
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